Nuance Pharma Announces License And Supply Agreement With Bavarian Nordic On The Development And Commercialization Of Respiratory Syncytial Virus (Rsv) Vaccine For Adults In China
By, Admin1 min read
Share
Bavarian Nordic To Receive Up To Usd 225 Million In Upfront And Milestone Payments In Addition To Tiered, Double-Digit RoyaltiesNuance Pharma Obtains Rights To Commercialize Mva-Bn
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
